Ortenau Klinikum — Clinical Trial Site

18 Registered trials

8 Currently recruiting

Organisation

Ortenau Klinikum

Location

Offenburg, Germany

Identifier

ORG-100030269

Address

Weingartenstrasse 70, Zell-Weierbach, 77654, Germany

Departments

Brustzentrum
Frauenklinik
Hämatologie und Onkologie
Hämatologie, Onkologie und Palliativmedizin
Hämatologie/Onkologie/Palliativmedizin
Hematology
Hematology/Oncology/Palliative Medicine
Medizinische Klinik Sektion Hämatologie und Onkologie
Medizinische Klinik II, Haematologie, Onkologie
Medizinische Klinik II, Hämatologie, Onkologie
Oncology
Onkologie
ORTENAU KLINIKUM Offenburg-Kehl
Radio-Onkologie

Clinical trials at this site (18)

Search interface

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised

2023-509861-19-00 Diffuse large B-cell lymphoma (DLBCL) 4
PREFer Recruiting

2024-520138-31-00 Early-stage favorable classic Hodgkin lymphoma 4 2026-06-01
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting

2023-509861-19-01 High-grade B-cell lymphoma (HGBL) 4 2025-09-30
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or … Recruiting

2023-507461-26-00 Newly diagnosed acute myeloid leukemia (AML) 5 2022-09-22
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended

2022-500571-32-00 Early-Stage Unfavorable Classical Hodgkin Lymphoma 4 2024-05-15
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol… Ended

2024-513949-37-00 previously untreated aggressive B-cell lymphoma 4 2023-03-16
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended

2024-514945-12-00 locally advanced resectable adenocarcinoma of the oesop 10 2018-09-03
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of… Ended

2024-512934-14-00 advanced or metastatic adenocarcinoma of the stomach or 5 2016-11-07
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15